Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL112 Single Ascending Dose in Stable Atherothrombotic Disease
NCT01499420Phase 2Completed
- Sponsor
- CSL Limited
- Start
- Feb 2012
- Primary completion
- Dec 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherothrombotic disease comparing CSL112 with Placebo (2 arms). Primary endpoints: Safety at 14 days and Clinically significant elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) at 14 days. Started Feb 2012; status: completed.
02
Drugs
CSL112
03
Conditions
atherothrombotic disease
Beyond the preview
Go deeper on NCT01499420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01499420.